boule-shutterstock-com-cherry-
Boule / Shutterstock.com
24 March 2016PharmaJoachim Wachenfeld and Oswin Ridderbusch

A second bite at the cherry

Second medical use claims have a long-standing history in European Patent Office (EPO) case law. As is well known, the first ever decision of the EPO’s Enlarged Board of Appeal confirmed the patentability of second medical use claims when written in the so-called Swiss-type format. The Enlarged Board in that 1984 decision, G5/83, held that protection was available for “specified new and inventive therapeutic application[s]”. In the years that followed the technical boards of appeal controversially discussed what exactly was meant by the “specified therapeutic applications” referred to by the Enlarged Board.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
6 August 2026   A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.
Pharma
31 July 2026   A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.
Pharma
23 July 2026   Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.